BLASUBCUTANEOUSSYRINGE
Approved
Oct 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Drug Shortage Active
PEGASYS is currently in shortage. Reason: Limited Availability. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
PEGASYS (peginterferon alfa-2a) by Adienne Pharma and Biotech is alfa-2a is an inducer of the innate antiviral immune response [see ] . Approved for chronic hepatitis c, chronic hepatitis b. First approved in 2002.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEGASYS is a pegylated interferon alfa-2a approved in 2002 for chronic viral hepatitis and other indications. It works by inducing the innate antiviral immune response to combat chronic infections including hepatitis B, C, D, and HIV, as well as hemophilia and melanoma. Administered subcutaneously via syringe, it represents an older immunomodulatory biologic now facing significant competitive pressure from newer antivirals and targeted therapies.
$0.151MPart D
LOE ApproachingDeclining
With LOE approaching and limited Part D spending ($151K, 53 claims in 2023), the PEGASYS brand team is likely small and focused on retention rather than growth initiatives.
Mechanism of Action
alfa-2a is an inducer of the innate antiviral immune response [see ] .
Pharmacologic Class:
Interferon alpha
Indications (2)
Worked on PEGASYS at Adienne Pharma and Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.